IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions

Experimental Brain Research

Volumn 178, Issue 4, 2007, Pages 462-469

  Jorgensen, Signe Humle ^a   Storm, Nicolas ^a   Jensen, Poul Erik Hyldgaard ^a   Laursen, Henning ^a   Sorensen, Per Soelberg ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Blood brain barrier; Experimental autoimmune encephalomyelitis; Intravenous immunoglobulin; Multiple sclerosis; Technetium 99m

Indexed keywords

HYDRAZINE NICOTINAMIDE CONJUGATED IMMUNOGLOBULIN G; IMMUNOGLOBULIN G; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DARK AGOUTI RAT; DISEASE PREDISPOSITION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG PENETRATION; EXTRAVASATION; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPINAL CORD; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFLAMMATION; MALE; RADIOPHARMACEUTICALS; RATS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 34147109292     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00221-006-0752-8     Document Type: Article

References (44)

1. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss HW, Fischman AJ (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31:2022-2028
2. Achiron A, Gabbay U, Gilad R, Hassin-baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398-402
3. Achiron A, Mor F, Margalit R, Cohen IR, Lider O, Miron S (2000) Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J Autoimmun 15:323-330
4. Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515-1520
5. Aihara N, Tanno H, Hall JJ, Pitts LH, Noble LJ (1994) Immunocytochemical localization of immunoglobulins in the rat brain: relationship to the blood-brain barrier. J Comp Neurol 342:481-496
6. Aktas O, Zipp F (2003) Regulation of self-reactive T cells by human immunoglobulins - implications for multiple sclerosis therapy. Curr Pharm Des 9:245-256
7. Aktas O, Waiczies S, Grieger U, Wendling U, Zschenderlein R, Zipp F (2001) Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto) antigen-specific T cells without inducing apoptosis. J Neuroimmunol 114:160-167
8. Andersson UG, Bjork L, Skansen-Saphir U, Andersson JP (1993) Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 79:211-216
9. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919
10. Bieber A, Asakura K, Warrington A, Kaveri SV, Rodriguez M (2000) Antibody-mediated remyelination: relevance to multiple sclerosis. Mult Scler 6(Suppl 2):S1-S5
11. de Bois MH, Arndt JW, van der Velde EA, van der Lubbe PA, Westedt ML, Pauwels EK, Breedveld FC (1992) 99mTc human immunoglobulin scintigraphy - a reliable method to detect joint activity in rheumatoid arthritis. J Rheumatol 19:1371-1376
12. Bolton SJ, Anthony DC, Perry VH (1998) Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 86:1245-1257
13. Buijs WC, Oyen WJ, Dams ET, Boerman OC, Siegel JA, Claessens RA, van der Meer JW, Corstens FH (1998) Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99Tcm. Nucl Med Commun 19:743-751
14. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221-1231
15. Dams ET, Oyen WJ, Boerman OC, Claessens RA, Wymenga AB, van der Meer JW, Corstens FH (1998) Technetium-99m labeled to human immunoglobulin G through the nicotinyl hydrazine derivative: a clinical study. J Nucl Med 39:119-124
16. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349:589-593
17. Fazekas F, Sorensen PS, Filippi M, Ropele S, Lin X, Koelmel HW, Fernandez O, Pozzilli C, O'Connor P, Enriquez MM, Hommes OR (2005) MRI results from the European study on intravenous immunoglobulin in secondary progressive multiple sclerosis (ESIMS). Mult Scler 11:433-440
18. Filippi M, Rocca MA, Pagani E, Iannucci G, Sormani MP, Fazekas F, Ropele S, Hommes OR, Comi G (2004) European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 61:1409-1412
19. Floris S, Blezer EL, Schreibelt G, Dopp E, van der Pol SM, Schadee-Eestermans IL, Nicolay K, Dijkstra CD, De Vries HE (2004) Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 127:616-627
20. Haas J, Maas-Enriquez M, Hartung HP (2005) Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over Wve years. Mult Scler 11:562-567
21. Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, Pozzilli C, O'Connor P (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149-1156
22. Humle Jorgensen S, Sorensen PS (2005) Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci 233:61-65
23. Jorgensen SH, Jensen PE, Laursen H, Sorensen PS (2005) Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurol Res 27:591-597
24. Juhler M, Laursen H, Barry DI (1986) The distribution of immunoglobulins and albumin in the central nervous system in acute experimental allergic encephalomyelitis. Acta Neurol Scand 73:119-124
25. Kaveri S, Prasad N, Vassilev T, Hurez V, Pashov A, Lacroix-Desmazes S, Kazatchkine M (1997) Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Mult Scler 3:121-128
26. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747-755
27. Koh CS, Gausas J, Paterson PY (1993) Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease. J Neuroimmunol 47:141-145
28. Lewanska M, Siger-Zajdel M, Selmaj K (2002) No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9:565-572
29. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717
30. Minagar A, Alexander JS (2003) Blood-brain barrier disruption in multiple sclerosis. Mult Scler 9:540-549
31. Ono M, Arano Y, Uehara T, Fujioka Y, Ogawa K, Namba S, Mukai T, Nakayama M, Saji H (1999) Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. Bioconjug Chem 10:386-394
32. Ono M, Arano Y, Mukai T, Uehara T, Fujioka Y, Ogawa K, Namba S, Nakayama M, Saga T, Konishi J, Horiuchi K, Yokoyama A, Saji H (2001) Plasma protein binding of (99m)Tc-labeled hydrazino nicotinamide derivatized polypeptides and peptides. Nucl Med Biol 28:155-164
33. Pashov A, Dubey C, Kaveri SV, Lectard B, Huang YM, Kazatchkine MD, Bellon B (1998) Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol 28:1823-1831
34. Pirko I, Ciric B, Gamez J, Bieber AJ, Warrington AE, Johnson AJ, Hanson DP, Pease LR, Macura SI, Rodriguez M (2004) A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J 18:1577-1579
35. Rizvi SA, Bashir K (2004) Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 63:S47-S54
36. Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121:259-262
37. Sorensen PS (2003) The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206:123-130
38. Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557-563
39. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen VA, Lee ML (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273-1281
40. Stangel M, Toyka KV, Gold R (1999) Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 56:661-663
41. Steffens MG, Oosterwijk E, Kranenborg MH, Manders JM, Debruyne FM, Corstens FH, Boerman OC (1999) In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations. J Nucl Med 40:829-836
42. Tonra JR, Reiseter BS, Kolbeck R, Nagashima K, Robertson R, Keyt B, Lindsay RM (2001) Comparison of the timing of acute blood-brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis. J Comp Neurol 430:131-144
43. Werring DJ, Brassat D, Droogan AG, Clark CA, Symms MR, Barker GJ, MacManus DG, Thompson AJ, Miller DH (2000) The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 123(Pt 8):1667-1676
44. Wuerfel J, Bellmann-Strobl J, Brunecker P, Aktas O, McFarland H, Villringer A, Zipp F (2004) Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 127:111-119